
NRIX Stock Forecast & Price Target
NRIX Analyst Ratings
Bulls say
Nurix Therapeutics Inc. has demonstrated a robust improvement in safety metrics for its drug candidates, with significant reductions in the prevalence of adverse events, enhancing the overall therapeutic profile of its pipeline drugs, particularly NX-5948 and NX-2127. The company’s progressing data and increasing study size indicate a favorable tolerability profile, supporting the potential for combination therapies in first-line and second-line settings for chronic lymphoblastic leukemia (CLL). With an estimated trajectory for potential accelerated approval by 2028 and a competitive edge in the treatment of triple-exposed CLL, the evolving data presents a compelling case for a positive market outlook for Nurix Therapeutics.
Bears say
Nurix Therapeutics Inc's stock outlook is negatively influenced by significant concerns regarding its clinical development trajectory and partnerships with major pharmaceutical companies. The company has experienced a decrease in median follow-up time for its candidates, which raises uncertainty about their effectiveness, as the duration of response has not been established. Additionally, the potential failure to successfully advance its DELigase platform and generate viable clinical candidates compounds the risks associated with its oncology pipeline, which may not be fully appreciated by the market.
This aggregate rating is based on analysts' research of Nurix Therapeutics, Inc and is not a guaranteed prediction by Public.com or investment advice.
NRIX Analyst Forecast & Price Prediction
Start investing in NRIX
Order type
Buy in
Order amount
Est. shares
0 shares